KNSA

Kiniksa Pharmaceuticals International Stock Analysis

AI Rating

Good
  • Quality7/10
  • Growth↑ 9/10
  • Value↓ 1/10
Kiniksa Pharmaceuticals International sales and earnings growth
KNSA Growth
Great
  • Revenue Y/Y↑ 56.71%
  • EPS Y/Y↑ 508.33%
  • FCF Y/Y↑ 275.31%
Kiniksa Pharmaceuticals International gross and profit margin trends
KNSA Profitability
Great
  • Gross margin ↑ 89.30%
  • EPS margin↓ 9.70%
  • ROIC 5Y↑ 3.56%
Kiniksa Pharmaceuticals International net debt vs free cash flow
KNSA Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Kiniksa Pharmaceuticals International stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks